Prostate cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients with abnormal prostate-specific antigen (PSA) elevated (>4.0 ng/ml) or abnormal digital rectal examination (DRE) or suspicious lesions found by prostate ultrasound, CT or MRI in the hospital; 2.Age/Gender: Adult male; 3.Patients who voluntarily participate in clinical trials and sign a written informed consent form for subjects;
Exclusion criteria
Exclusion criteria: 1.Patients with pacemakers, unknown materials, metal implants in the body, neurostimulators, and claustrophobia; 2.Patients who underwent biopsy, local ablation, prostate surgery, or endocrine therapy, chemotherapy, radiotherapy and other anti-tumor treatments before examination;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRI measurements_Time-dependent DWI_Intracellular Volume Fraction;MRI measurements_Time-dependent DWI_Extracellular diffusion coefficient;MRI measurements_Time-dependent DWI_Cell diameter;Lesion size;Pathological Gleason grading;Anatomical location of lesion;Status of Lymph node and bone metastasis;Status of invasion of capsule and seminal vesicle;Prostate volume measured by MRI;MRI measurements_Time-dependent DWI_Cellularity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Prostate-specific antigen;Blood pressure;Surgical margin;History of hypertension;History of Drinking;Weight;BMI;Immunohistochemical results;Tumor staging;Invasion status of capsule and seminal vesicle;Surgical history;Digital rectal examination;History of diabetes;Age;Height;Smoking history;Lymph node status;Tumor size; | — |
Countries
China
Contacts
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology